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ABSTRACT
Kawasaki disease (KD) is an acute self-limiting
inﬂammatory disorder, associated with vasculitis,
affecting predominantly medium-sized arteries,
particularly the coronary arteries. In developed countries
KD is the commonest cause of acquired heart disease in
childhood. The aetiology of KD remains unknown, and it
is currently believed that one or more as yet unidentiﬁed
infectious agents induce an intense inﬂammatory host
response in genetically susceptible individuals. Genetic
studies have identiﬁed several susceptibility genes for KD
and its sequelae in different ethnic populations,
including FCGR2A, CD40, ITPKC, FAM167A-BLK and
CASP3, as well as genes inﬂuencing response to
intravenous immunoglobulin (IVIG) and aneurysm
formation such as FCGR3B, and transforming growth
factor (TGF) β pathway genes. IVIG and aspirin are
effective therapeutically, but recent clinical trials and
meta-analyses have demonstrated that the addition of
corticosteroids to IVIG is beneﬁcial for the prevention of
coronary artery aneurysms (CAA) in severe cases with
highest risk of IVIG resistance. Outside of Japan,
however, clinical scores to predict IVIG resistance
perform suboptimally. Furthermore, the evidence base
does not provide clear guidance on which corticosteroid
regimen is most effective. Other therapies, including
anti-TNFα, could also have a role for IVIG-resistant KD.
Irrespective of these caveats, it is clear that therapy that
reduces inﬂammation in acute KD, improves outcome.
This paper summarises recent advances in the
understanding of KD pathogenesis and therapeutics, and
provides an approach for managing KD patients in the
UK in the light of these advances.
INTRODUCTION
Kawasaki disease (KD) affects 8.1/100 000 children
under the age of 5 years in the UK, and is the com-
monest cause of acquired heart disease in children
in developed countries.1–3 KD probably represents
an aberrant inﬂammatory host response to one or
more as yet unidentiﬁed pathogen(s), occurring in
genetically predisposed individuals.2 4 5 KD is asso-
ciated with systemic vasculitis particularly affecting
the coronary arteries, causing coronary artery
aneurysms (CAA) in 15–25% of untreated patients
while 2–3% of untreated cases die as a result of
coronary vasculitis.6–9 In view of the frequency and
severity of coronary artery complications, there has
been intense interest in treatments to reduce the
risk of CAA.6 10–14 KD is also potentially an
important cause of long-term cardiac disease in
adult life.6 7 Notably, as more children with KD are
advancing into adulthood, further studies are
needed to (1) improve our understanding of long-
term cardiac sequelae, (2) optimise therapy in
childhood to minimise risks in adulthood and to
ensure the continuation of quality, evidence-based
care for KD patients as they transit to adult
services.
The purpose of this article is to summarise
recent advances in our understanding of the patho-
genesis and treatment of KD, and to provide an
approach to managing KD in the UK in the light of
these advances. The updated guidelines are based
on evidence from meta-analyses and randomised
controlled trials (RCTs), and will highlight areas of
practice where evidence remains weak. Last, sugges-
tions for future research are outlined.
EPIDEMIOLOGY
KD is the second commonest vasculitic illness of
childhood after Henoch Schönlein purpura and the
commonest cause of acquired heart disease in chil-
dren in developed countries.3 6 9 15 The disease has
a world-wide distribution with a male preponder-
ance, an ethnic bias towards Asian children (par-
ticularly East Asian), seasonality and occasional
epidemics.6 9 16 The incidence in Japan is 138/100
000 in children younger than 5 years, whereas in
the USA, it is 17.1/100 000, and in the UK 8.1/
100 000.1 3 15 17 Variation in awareness among
clinicians of KD, and differences between countries
and regional referral patterns may contribute to
some of these epidemiological differences,
however, the majority of these differences are likely
to be the result of ethnic and racial differences in
susceptibility and in exposure to a presumed patho-
gen.18 Approximately 85% of children with KD are
younger than 5 years of age, with peak age inci-
dence at 18–24 months; patients aged less than
3 months, or more than 5 years are encountered
less commonly, but are at increased risk for CAA
formation.1 3 15 17
AETIOPATHOGENESIS
Infectious trigger
The aetiology of KD remains unknown.
Pronounced seasonality and clustering of KD cases
have led to the hunt for infectious agents as a
cause. So far, however, no single agent has been
consistently identiﬁed.19–21 Many published reports
implicate a number of bacterial and viral pathogens,
including retroviruses, Epstein–Barr virus, corona-
virus, propionibacterium acnes, staphylococcal and
streptococcal superantigens, and unidentiﬁed virus
particles as infectious triggers of KD.2 5 To date, no
single pathogen has been conﬁrmed in subsequent
studies. The debate regarding the infectious cause
of KD has centred around the mechanism of
immune activation: conventional antigen versus
superantigen (SAg).22 23 Superantigens seemed a
plausible cause of the disorder in view of the clin-
ical and immunological similarity between KD and
staphylococcal and streptococcal superantigen-
mediated disorders. Several studies have presented
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evidence supporting superantigen-triggered process, but others
have not conﬁrmed the association.5 22 24 One explanation for
the inconsistent ﬁnding is that KD is triggered by a range of dif-
ferent superantigens, and animal studies suggest the possibility
that both superantigen, and Toll-like receptor agonists may need
to act synergistically.5 25 Against a superantigen (SAg)-mediated
process is the report by Rowley et al26 of three fatal cases of KD
in which IgA plasma cell inﬁltration into the vascular wall
during the acute phase of the illness was observed. By examin-
ing the clonality of this IgA response using reverse transcriptase
(RT)-PCR in lesional vascular tissue, these researchers observed
that the IgA response was oligoclonal, suggesting a conventional
antigenic process rather than a superantigenic-driven one.26
Although uncertainty remains regarding the mechanism(s) of
initial immune activation, most authorities believe that one or
more potentially ubiquitous infectious agents produces a dele-
terious host response in a genetically susceptible subject.2 5 9
Genetics
A genetic contribution to the risk of KD is suggested by the
much higher risk of the disease in Asian children, particularly
the Japanese and Koreans, which persists when patients of these
ethnicities migrate to other countries27; from the observed
increased relative risk to siblings of index cases compared with
the general population, from twin studies and from well docu-
mented multicase families.28
Many candidate genes have previously been suggested, either
as susceptibility genes for developing KD; or increasing risk of
CAA.29–31 These are summarised elsewhere.31 Most of these
earlier studies, however, failed to identify deﬁnitive genetic asso-
ciations, emphasising the difﬁculties of the candidate gene
approach for a disease where the pathogenesis is poorly under-
stood.32 By contrast with the candidate gene approach, genome-
wide association studies (GWAS) have the advantage of identify-
ing disease-associated genes without requiring prior knowledge
of the mechanisms involved.32 A number of GWAS of KD have
been published so far.33–39 From these studies, several single
nucleotide polymorphisms (SNPs) associated with susceptibility
to KD, including ITPKC, ABCC4 and FCGR2A, CD40 and a
gene region near FAM167A-BLK (table 1). Furthermore, other
genes have been associated with non-response to intravenous
immunoglobulin (IVIG) and risk of CAA, including CASP3,
FCGR3B and genes of the TGF-β signalling pathway.40 41 It is
likely that many other genetic factors have yet to be identiﬁed,
as the GWAS methodology has so far only identiﬁed the most
signiﬁcant associations.32 Whole exome sequencing studies
applied to individual KD cases of extreme phenotype, such as
those with giant CAA, could clarify the contribution of rarer
genetic variants in these extreme cases. Thus, the study of the
genetic contribution to KD remains an intense area of research
worldwide, and still very much a work in progress.
CLINICAL MANIFESTATIONS AND DIAGNOSIS
There is no diagnostic test for KD, thus the diagnosis rests
on combinations of clinical criteria and laboratory ﬁndings
(table 2). For the diagnosis to be established according to the
Diagnostic Guidelines of the Japan KD Research Committee,
ﬁve of the six criteria in table 2 should be present.42 The North
American recommendations for the diagnosis are similar, except
Table 1 Genome-wide association studies in Kawasaki disease (KD)
Gene Locus Population Biological significance References
FCGR2A (encodes low-affinity
immunoglobulin gamma Fc region
receptor II-a)
1q23 European, Asian The involvement of FCGR2A in susceptibility to KD highlights the importance of
IgG receptors in the pathogenesis of this inflammatory disease and provides a
biological basis for the use of intravenous immunoglobulin for treatment.
37
ITPKC (inositol 1,4,5-trisphosphate
3-kinase C)
19q23 Japanese,
American
ITPKC acts as a negative regulator of T-cell activation through the Ca2+/NFAT
signalling pathway, and the C allele may contribute to immune hyper-reactivity in
KD. This finding provides new insights into the mechanisms of immune activation
in KD and emphasises the importance of activated T cells in the pathogenesis of
this vasculitis
36
ABCC4 (ATP-binding cassette, subfamily
C, member 4)
13q32 European,
American,
Australian
ABCC4 is a multifunctional cyclic nucleotide transporter that stimulates the
migratory capacity of dendritic cells and a mediator of prostaglandin efflux from
human cells inhibited by non-steroidal anti-inflammatory medications such as
aspirin.
38
Intergenic region between FAM167A and
BLK
8p22-23 Japanese Variations in the FAM167ABLK region have been associated with several
autoimmune diseases, such as rheumatoid arthritis, systemic lupus
erythematosus, and systemic sclerosis. BLK encodes B-lymphoid tyrosine kinase, a
Src family tyrosine kinase downstream of the B-cell receptor. Mechanism in KD
pathogenesis unknown.
34
CD40 20q12–
q13.2
Taiwanese,
Japanese
CD40 L is expressed on the surface of CD4 T-cells and platelets, and engages
with CD40 expressed on the surface of antigen-presenting cells or endothelial
cells. Transduces signals related to cell activation or development. Elevated
expression of CD40 L during acute-phase KD, and significantly higher expression
in KD patients with CAA have been reported.
34
CAA, coronary artery aneurysms; NFAT, nuclear factor of activated T cells.
Table 2 Kawasaki disease: diagnostic criteria. KD may be
diagnosed with fewer than 4 of these features if coronary artery
abnormalities are detected
Criterion Description
Fever Duration of 5 days or more PLUS 4 of 5 of the
following:
1. Conjunctivitis Bilateral, bulbar, non-suppurative
2. Lymphadenopathy Cervical, often >1.5 cm
3. Rash Polymorphous, no vesicles or crusts
4. Changes in lips or oral
mucosa
Red cracked lips; ‘strawberry’ tongue; or diffuse
erythema of oropharynx
5. Changes of extremities Initial stage: erythema and oedema of palms and
soles Convalescent stage: peeling of skin from
fingertips
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that fever is a mandatory criterion, and four of the remaining
ﬁve criteria are required to establish the diagnosis.6 However, in
addition to patients fulﬁlling the criteria for complete KD,
many patients have some but not all of the clinical features of
KD. These patients may still be, or are, at risk of CAA.
Diagnosis of these ‘Incomplete KD’ cases depends on a high
level of suspicion in children presenting with some of the KD
features and evidence of systemic inﬂammation (such as elevated
C-reactive protein (CRP), erythrocyte sedimentation rate (ESR),
or leucocytosis). Early echocardiography may reveal evidence of
coronary vasculitis, conﬁrming the diagnosis of KD in this
patient group. A negative echocardiogram does not exclude the
diagnosis of KD. In addition to the diagnostic challenge of
incomplete cases, the requirement within the existing diagnostic
criterion for a fever of greater than 5 days may also lead to
delayed treatment. While duration of fever has historically been
of importance for the standardisation of case deﬁnitions, clini-
cians should not delay in making a diagnosis of KD and institut-
ing treatment (see below) if: (1) 5/6 diagnostic criteria of KD
are present before day 5 of fever; (2) CAA or coronary dilata-
tion are present, or (3) evidence of persistent elevation of
inﬂammatory markers with no other explanation in patients
where there remains clinical suspicion of KD.2 6 9 We recom-
mend seeking early expert advice in such cases.
Irritability is an important sign which is nearly always
present, although interestingly not included as one of the diag-
nostic criteria.9 43 The exact mechanism of the irritability is
unclear, but it may be related to the presence of aseptic menin-
gitis.9 43 Another important clinical sign is the development of
erythema and induration at the site of previous Bacillus
Calmette–Guérin (BCG) immunisation.9 44 The mechanism of
this clinical sign is believed to be due to cross-reactivity of T
cells in KD patients between speciﬁc epitopes of mycobacterial
and human heat-shock proteins.9 44 The diagnostic criteria may
present sequentially, such that a so-called ‘incomplete’ case can
evolve with time into a ‘complete’ case.6 Thus, the diagnosis of
KD must be considered in any child with a febrile exanthema-
tous illness and evidence of inﬂammation, particularly if it per-
sists longer than 4–5 days.
Other relatively common clinical ﬁndings in KD include arth-
ritis, aseptic meningitis, pneumonitis, uveitis, gastroenteritis,
meatitis and dysuria and otitis.2 9 Relatively uncommon abnor-
malities include, hydrops of the gallbladder, gastrointestinal
ischaemia, jaundice, cranial nerve palsy, renal involvement
(pyuria, proteinuria, tubular disturbances, tubulointerstitial
nephritis and renal failure), petechial rash, shock syndrome,
febrile convulsions and encephalopathy or ataxia.2 9 Additional
rare complications of KD include macrophage activation syn-
drome (secondary haemophagocytic lymphohistiocytosis), and
syndrome of inappropriate antidiuretic hormone secretion
resulting in hyponatraemia.45 46
Vascular involvement
The main sites of clinically important vascular involvement are
the coronary arteries, although other vessels such as the axillary
arteries can be involved. CAA occur in 15–25% of untreated
cases, with additional cardiac features in a signiﬁcant proportion
of these including pericardial effusion, electrocardiographic
abnormalities, pericarditis, myocarditis, valvular incompetence,
cardiac failure and myocardial infarction.6 When systemic arter-
ial injury (major limb arteries, renal and other visceral vessels)
occurs, it is rarely seen in the absence of CAA.2
Laboratory ﬁndings
KD is invariably associated with an inﬂammatory process, with
elevation of ESR, CRP and white cell count.2 6 9 In the absence
of signiﬁcant inﬂammation, the diagnosis of KD is unlikely.2 6 9
Not all the inﬂammatory markers may be abnormal at ﬁrst pres-
entation, and repeat blood testing should be undertaken if there
is diagnostic uncertainty. Thrombocytosis occurs towards the
end of the second week of the illness and, therefore, may not be
helpful, diagnostically, in the early stages.2 6 9 Acute thrombo-
cytopenia or low/normal platelet count may occur and may be
associated with a poorer prognosis (see below).2 6 9 47 Liver
function may be deranged and some patients present with jaun-
dice and elevation of transaminases.2 6 9 Hypoalbuminaemia is
common; sterile pyuria and cerebrospinal ﬂuid (CSF) pleocyto-
sis (predominantly lymphocytes) representing aseptic meningitis
also occur.2 6 9 48
Predicting IVIG resistance/high CAA risk
Several scoring systems have been developed to identify children
at highest risk of IVIG resistance and, hence, highest risk of
developing CAA (table 3).47 49 50 Kobayashi et al47 developed a
model to predict unresponsiveness to IVIG in Japanese children
with KD. This was used to deﬁne severe cases in a pivotal
Table 3 Scoring systems for predicting IVIG resistance
EGAMI49 KOBAYASHI47 SANO50
Na ≤133 (2 points) Total bilirubin ≥0.9 mg/dl (1 point)
≤4 days of illness (1 point) ≤4 days of illness (2 points)
ALT >100 U/L (1 point) ALT≥ 100 U/L (1 point) AST ≥200 U/L (1 point)
≤300 ×[109/L platelets (1 point) ≤300×109 /L platelets (1 point)
CRP ≥8 mg/dL (1 point) CRP≥10 mg/dL (1 point) CRP≥7 mg/dL (1 point)
Age ≤6 months (2 points) Age ≤12 months (1 point)
≥80% neutrophils (2 points)
High risk ≥3 points ≥5 points ≥2 points
Test performance in Japanese vs non-Japanese
Japanese cases
Sensitivity (%) 78 86 77
Specificity (%) 76 67 86
Non-Japanese cases51
Sensitivity (%) 42 33 40
Specificity (%) 85 87 85
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; IVIG, intravenous immunoglobulin.47 49–51
Eleftheriou D, et al. Arch Dis Child 2013;0:1–10. doi:10.1136/archdischild-2012-302841 3
Review
 group.bmj.com on December 6, 2013 - Published by adc.bmj.comDownloaded from 
clinical trial of corticosteroids(see below), because IVIG resist-
ance is known to be a strong risk factor for the development of
CAA. The Kobayashi, Egami and Sano scores when tested in a
USA study demonstrated comparably high speciﬁcity for predict-
ing IVIG non-response in non-Japanese patients, but had low
sensitivity.51 The clinical implication of this is that if the risk
score is ‘positive’ in a non-Japanese patient (eg, ≥5 for the
Kobayashi score) then IVIG resistance is likely; however, a nega-
tive score does not reliably exclude IVIG resistance. Attempts to
develop a more sensitive and speciﬁc score for patients outside
of Japan have thus far been unsuccessful.52
TREATMENT
IVIG
Early recognition and treatment of KD with aspirin and IVIG
has been shown unequivocally by randomised controlled
trials and meta-analysis to reduce the occurrence of CAA.6 53
Two g/kg of IVIG is the optimal dose, usually given as a single
infusion.6 53 Meta-analysis of randomised controlled trials com-
paring divided lower doses of IVIG (400 mg/kg/day for four
consecutive days) versus a single infusion of high-dose IVIG
(2 g/kg over 10 h) has shown that even though the 4-day
regimen has some beneﬁt, the single-dose regimen has a greater
therapeutic effect in the prevention of CAA.54
Aspirin
Meta-analysis comparing anti-inﬂammatory doses of aspirin
(30–50 mg/kg/day) with high-dose aspirin (80–120 mg/kg/day)
combined with IVIG found no signiﬁcant difference in the inci-
dence of CAA between the groups.55 Currently, aspirin at a dose
of 30–50 mg/kg/day is recommended during the acute phase of
the illness, as this may be better tolerated than higher doses in
terms of gastrointestinal and other side effects. The dose should
be reduced to an antiplatelet dose of 3–5 mg/Kg once fever and
inﬂammation have subsided.
Corticosteroids for the primary treatment of severe KD
IVIG resistance occurs in up to 20% of cases, and these patients
are at increased risk of developing CAA unless they receive add-
itional treatment.2 6 9 Recently, the ﬁndings of the published
RAISE study that selected patients at high risk of IVIG non-
response emphasised this point as treatment of the control arm
with IVIG/ aspirin was still associated with a CAA complication
rate of 23%.14
Corticosteroids are effective treatment for other forms of vas-
culitis, but early retrospective analyses suggested that corticos-
teroids were associated with increased risk of CAA.56 However,
this almost certainly reﬂected selection bias as the sickest
patients received steroids.
Clinical trials evaluating the use of corticosteroids plus IVIG
have produced seemingly confusing results.10 11 14 57–59 Chen
et al60 recently reported a meta-analysis comparing the fre-
quency of CAA in patients treated with IVIG plus corticoster-
oids or IVIG alone for the primary treatment of KD. They
followed standard guidelines for conduct of meta-analyses, and
used deﬁned criteria for trial quality assessment, including
evaluation of criteria for diagnosis; study design; follow up and
blinding.60 They identiﬁed nine clinical studies meeting their
quality criteria, involving 1011 patients. Six out of nine were
prospective RCTs; two were non-randomised controlled studies;
and one was a retrospective report.60 Of the 1011 patients
included, 536 received IVIG+corticosteroids and 475 IVIG
alone.60 They found that signiﬁcantly fewer patients receiving
IVIG+corticosteroids developed CAA than those receiving IVIG
alone (7.6% vs 18.9%; OR: 0.3; 95% CI 0.20 to 0.46).60 The
beneﬁt was found in several subgroup analyses including the six
prospective RCTs, and studies using prednisolone or intravenous
methylprednisolone.60 They found no signiﬁcant differences in
frequency of severe adverse events between the steroid and non-
steroid treatment groups.60 Chen’s meta-analysis provides con-
vincing evidence that steroids combined with IVIG as initial
treatment reduces overall risk of CAA in severe KD.60 However,
neither the meta analysis nor the RAISE study provides clear
answers as to whether all children in the UK should be treated
with corticosteroids, and what dose, duration and route of corti-
costeroids should be used.
Heterogeneity in corticosteroid dosing in the published trials
is an important consideration when translating the results of
Chen’s meta-analysis into clinical practice, as different cortico-
steroid regimens were used in each of the trials. This is illu-
strated when two of the methodologically strongest studies, the
American Paediatric Heart Network study10 and the recently
reported Japanese RAISE study14 are considered in more detail.
The American study evaluated the use of intravenous methyl-
prednisolone (30 mg/kg) given as a single dose in unselected
patients with KD.10 By contrast, RAISE evaluated lower-dose
(2 mg/kg) intravenous prednisolone given for 5 days; if fever
settled, this was then converted to oral prednisolone which was
subsequently tapered over 15 days only after the CRP normal-
ised.14 Moreover, patients were included in RAISE only if they
were at high risk of IVIG resistance based on the Kobayashi
score.14 Perhaps unsurprisingly then, these two studies have pro-
duced conﬂicting results, with steroids conferring signiﬁcant
beneﬁt in the Japanese RAISE study, but a lack of overall beneﬁt
in the American study.
Second, as seven of the nine studies in the meta-analysis were
undertaken in Japan and only two in the USA, the results may
not be applicable outside of Japan. There is some concern that
KD in Japan may behave differently from the disease in
non-Japanese populations, highlighted by the failure of the
Kobayashi and other scores used to predict IVIG non-response
in Japan to accurately predict non-response to IVIG in the
USA.14 47 51 The meta-analysis may say more about the beneﬁ-
cial effect of steroids in Japanese patients meeting the criteria
for predicted IVIG resistance than about an overall beneﬁt in
unselected patients.
Third, while the meta-analysis has not revealed any increase
in severe adverse events associated with corticosteroid use, the
total number of patients receiving steroids was only about
500.60 Most paediatricians who routinely use corticosteroids for
the treatment of other systemic inﬂammatory diseases will prob-
ably be comfortable with a modest dosing regimen of prednisol-
one weaning over 3 or 4 weeks, if this truly will spare some
children from potentially lifelong cardiac sequelae, although
vigilance during follow-up for the presence of
corticosteroid-related complications, such as hypertension,
behavioural changes, secondary infection, hyperglycaemia and
bone necrosis is required.
As 80% of patients with KD respond to aspirin and IVIG,
and CAA are most commonly seen in those who fail to respond
to IVIG, we urgently need a means of predicting IVIG resistance
so that corticosteroids can be included in primary treatment of
selected patients at risk of IVIG non-response. However, the
Kobayashi score, used by Japanese investigators had low sensi-
tivity (but good speciﬁcity, table 3) for the prediction of IVIG
non-response in studies in the USA.14 51 Therefore, a low
Kobayashi score does not reliably exclude IVIG resistance. With
these caveats in mind, we propose a pragmatic treatment
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approach (below) based on the current data, while advocating
further research to provide the evidence base, which is currently
lacking.
Recommended indication for corticosteroids in KD
We suggest that corticosteroids should be considered for
1. Patients who have already declared themselves as
IVIG-resistant, that is, with ongoing fever, and/or persistent
inﬂammation or clinical signs ≥48 h after receiving IVIG as
a single dose of 2 g/kg.
2. Patients with features of the most severe disease (and there-
fore the greatest likelihood of developing CAA). In the
absence of validated risk scores outside of Japan, we suggest
that such patients include the very young (<1-year-old);
those with markers of severe inﬂammation, including: per-
sistently elevated CRP despite IVIG, liver dysfunction,
hypoalbuminaemia, and anaemia; and the small group who
develop features of haemophagocytic lymphohistiocytosis
(HLH)61 and/or shock.
3. Patients who already have evolving coronary and/or periph-
eral aneurysms with ongoing inﬂammation at presentation. It
is increasingly recognised that echocardiographic studies per-
formed in the ﬁrst week of KD may already show vessel
abnormality, including brightness (suggesting inﬂammation)
or dilatation when compared with age-related normal ranges
and/or extracoronary manifestations, including mitral regur-
gitation and pericardial effusion.62 Patients with these fea-
tures may also be at greater risk of CAA and, therefore, may
require corticosteroids.62
What corticosteroid regimen to use?
Chen’s meta-analysis does not provide us with an evidence base
for optimal corticosteroid dose/duration.60 From the studies
included, an intravenous preparation equivalent to 2 mg/kg
prednisolone for 5–7 days, or until CRP normalises, followed
by oral prednisolone weaning over 2–3 weeks seems logical.
However, in the absence of a robust evidence base, ﬂexibility of
the steroid regimen ultimately used for individual patients is
recommended, and should ultimately be determined by treating
clinicians: the updated guideline provides two suggested regi-
mens (ﬁgure 1).
Should a second dose of IVIG be given to patients who fail
to respond to the initial dose?
In patients who have shown some but not complete response,
we suggest that a second dose of IVIG is given at the same time
as commencing steroids if they have not already been com-
menced for signs of severe disease (see above). A second dose
may not be beneﬁcial if there was little response to the ﬁrst
dose. Vigilance during follow-up for the presence of
corticosteroid-related complications, such as hypertension, sec-
ondary infection, hyperglycaemia and bone necrosis is required.
Role of antitumour necrosis factor-α
There are emerging animal data case reports suggesting a role
for anti-tumour necrosis factor (TNF)-α therapy for the treat-
ment of KD.63–66 Serum TNF-α is elevated in KD patients, and
higher levels correlate with the development of CAA.67 The
most commonly used agent is inﬂiximab, a chimeric murine/
human IgG1 monoclonal antibody speciﬁcally binding
TNF-α.63–66 In one retrospective study of 17 children with
IVIG-resistant KD, inﬂiximab was used successfully with abrupt
defervescence in 13/16 febrile patients, with no infusion reac-
tions.12 Burns et al68 reported a phase 2 clinical trial including
16 patients receiving inﬂiximab that demonstrated that this
treatment was safe and well tolerated in patients resistant to
IVIG. Response to therapy with cessation of fever occurred in
13 of 16 patients. CRP level was elevated in all but one patient
before inﬂiximab infusion, and the level was lower following
infusion in all 10 patients in whom it was remeasured within
48 h of treatment.68 There were no infusion reactions to inﬂixi-
mab, and no complications attributed to inﬂiximab administra-
tion in any of the patients.68 A more recent US retrospective
review of IVIG-resistant patients treated with either IVIG
(n=86) or inﬂiximab (n=20) demonstrated that patients treated
with inﬂiximab had fewer days of fever and shorter hospitalisa-
tion, but with similar coronary artery outcomes.69
Etanercept (soluble TNF-α receptor) is an alternative TNF
antagonist, and has been reported to be safe and well tolerated
in 15 children with KD when given at a dose of 0.8 mg per kilo-
gram weekly for three doses, and may be beneﬁcial.70 A recent
multicentre study in the USA comparing IVIG and aspirin to
IVIG/aspirin plus inﬂiximab as initial therapy in an unselected
group of KD patients has been completed and showed no sig-
niﬁcant reduction in CAA, although the trial was underpowered
for this endpoint. There was, however, faster resolution of the
acute-phase response in the inﬂiximab group. (Burns JC et al,
personal communication and manuscript submitted). Thus,
anti-TNFα should be considered in patients with IVIG-resistant
KD, and further study is required of its role as ﬁrst-line therapy.
Other therapies
Other immunosuppressive agents such as ciclosporin, cyclophos-
phamide, methotrexate, and plasma exchange, have occasionally
been used to treat patients who do not respond to IVIG, ster-
oids and anti-TNFα.2 6 Genome-wide association studies have
identiﬁed polymorphisms of ITPKC, a negative regulator of
T-cell activation, and other T cell signalling pathway genes asso-
ciated with KD susceptibility, IVIG resistance, and increased risk
of CAA in Asian and US children.36 40 This suggests that calci-
neurin inhibitors (such as ciclosporin) may be applicable for the
treatment of KD.71 72 These initial reports need to be tempered
by the knowledge that calcineurin inhibitors can also be toxic to
the endothelium; for example, in Behçet’s disease it is recom-
mended that these are avoided in those with cerebral vasculitis
since there is a concern that this class of drug may exacerbate
vasculitic complications in some scenarios.6 73 The use of these
agents cannot be recommended routinely but can be considered
on a case-by-case basis after consultation with specialist units.
Management of KD in the convalescent phase
In the convalescent phase of the condition, if aneurysms persist,
antiplatelet therapy in the form of low-dose aspirin (2–5 mg/kg)
should be continued long-term until the aneurysms resolve.6
Clopidogrel is an alternative antiplatelet agent that could be
considered.6 In the presence of giant aneurysms (>8 mm) war-
farin is recommended in addition to aspirin.74 Heparin should
be administered initially for at least 48 h and only stopped when
warfarin has been commenced and the international normalised
ratio (INR) is stable between two and three to avoid paradoxical
thrombosis due to protein C and S depletion that may occur
when warfarin treatment is started.9 If thrombosis does occur,
thrombolytic therapy may be indicated, but expert advice must
be sought.6 9 Some patients may require coronary angioplasty or
a revascularisation procedure should ischaemic symptoms arise
or evidence of obstruction occur.6 If formal catheter coronary
arteriography is to be considered, if possible, this should be
deferred for the ﬁrst 6 months from the acute illness to avoid
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procedural-related myocardial infarction, of particular concern,
while the coronary endothelium is still actively inﬂamed.6
Immunisation following KD
The recommendation regarding timing of immunisations after
KD remains unchanged from our 2002 guideline.9
Immunisation with all vaccines should be deferred for at least
3 months following an episode of KD treated with IVIG, mainly
due to the potential lack of effectiveness of live vaccines follow-
ing IVIG75 and due to the potential for any vaccine to induce
potentially detrimental immune activation during the convales-
cent phase of KD. The evidence for this latter recommendation
is anecdotal. Thereafter, all vaccines should be administered as
recommended by national schedules.
Patients who require long-term aspirin for persistent CAA
should be considered for immunisation with varicella zoster
virus (VZV) vaccine in view of the association of VZV and
aspirin with Reye’s syndrome.
CARDIAC COMPLICATIONS OF KD
Prognosis is largely determined by cardiac sequelae of KD.2 6 9
The outlook for KD patients who have normal coronary echo-
cardiographic ﬁndings or only mild dilation on assessment
6 weeks after the onset is generally good.2 6 9 However, those
patients with persistent coronary artery dilatation and aneur-
ysms are at risk of coronary artery stenosis or thrombosis. In
1993, a British Paediatric Surveillance Unit (BPSU) study indi-
cated a mortality rate of 3.7% in the UK for KD76; at the time
of this writing, a repeat BPSU survey is ongoing, and will
Figure 1 Recommended clinical guideline for the management of Kawasaki disease in the UK. Since risk scores for IVIG resistance perform sub-
optimally in non-Japanese patients (Table 3), we cannot recommend their use to deﬁne high risk deﬁnitively; clinicians may, however, choose to
consider the clinical and laboratory parameters listed to identify “high risk” patients. If the Kobayashi risk score is “positive” in a non-Japanese
patient (eg,≥ 5) then IVIG resistance is likely; however a score <5 does not reliably exclude IVIG resistance. The aim of treatment is to switch off
the inﬂammatory process that is damaging the coronary arteries as rapidly as possible. In the absence of a strong evidence base favouring a speciﬁc
corticosteroid regimen, two suggested corticosteroid regimens for high-risk cases are provided for clinicians to choose from. For those on low dose
aspirin, we also recommend avoiding the concomitant use of non-steroidal anti-inﬂammatory drugs (NSAIDs) as these interfere with the anti-platelet
effect of low dose aspirin. *Treatment can be commenced before 5 days of fever if sepsis excluded; treatment should also be given if the
presentation is > 10 days from fever onset if there are signs of persistent inﬂammation; **Kobayashi risk score ≥5 points aRefer to paediatric
cardiologist; ¶ Other speciﬁc interventions such as positron emission tomography (PET) scanning, addition of calcium channel blocker therapy, and
coronary angioplasty at discretion of paediatric cardiologist. + Other immunomodulators may include ciclosporin. ♥For infants, Z score for internal
coronary artery diameter >7 based on Montreal normative data: http://parameterz.blogspot.co.uk/2010/11/montreal-coronary-artery-z-scores.html.
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provide more up-to-date outcome data for the UK.
Angiographic resolution 1–2 years after onset of disease has
been observed in 50–70% of vessels with coronary aneurysms;
giant aneurysms never resolve completely.77–79 In a study
exploring the long-term outcomes of a cohort of 6576 patients
with KD enrolled between 1982 and 2004, the mortality rate
for patients without cardiac sequelae in the acute phase of the
disease, and for female patients with sequelae, did not differ
from the normal population.80 The all-cause mortality rate of
males with cardiac sequelae was, however, 2.4 times higher than
the normal population.80
All patients with KD should undergo echocardiography at
diagnosis and 6–8 weeks after the onset of the disease.6 9 An
intermediate echocardiogram at 10–14 days of disease onset
should be performed if the initial echo was normal and the
disease activity has been arrested.6 9 Echocardiography should
be performed at least weekly in those with aneurysms detected
on initial echocardiography (ECHO) and those with ongoing
active inﬂammation to monitor aneurysm size progression, or
the development of thrombus formation.6 9 Long-term aspirin
at 2–5 mg/kg/day is recommended for those with persisting
aneurysms on echocardiography.6 9 This can be discontinued if
the aneurysms resolve. Depending on the size of the aneurysms,
electrocardiography and echocardiography performed 6–12
monthly is recommended.6 9
In patients with persistent aneurysms beyond 6 weeks, long-
term cardiovascular follow-up into adult life is required.6 9
There may be echocardiographic resolution of the aneurysm
over time.6 9 This is due to vessel remodelling, with ﬁbrosis,
and proliferation of subendothelial tissues.6 9 The lesion may
remain thickened and abnormal even after echocardiographic
resolution.6 9
The prognosis is guarded for those with giant aneurysms.6 9
A recent single-centre study described a cohort of 76 Japanese
KD patients with giant aneurysms (>8 mm internal diameter)
who had a 30-year survival rate of 88%, and a cumulative inter-
vention rate (catheter or surgical) of 59%, 25 years postacute
KD81; 16% developed myocardial infarction.81 As more patients
with a history of KD and coronary aneurysms reach young
adulthood, acute mycocardial infarction due to thrombosis of
aneurysms, or due to progressive arterial stenosis from aneur-
ysm remodelling is of increasing concern.82 83 Of note, percu-
taneous transluminal coronary angioplasty is associated with a
high rate of restenosis or occlusion in KD patients, thus rota-
tional ablation or bypass surgery may be advisable as an alterna-
tive procedure.83 Intravascular ultrasound (IVUS) can play an
important role during interventions in patients with a history of
KD by helping to determine the extent of arterial calciﬁcation,
and by evaluating intervention results to ensure proper stent
sizing and placement.83 84 Coronary artery bypass graft (CABG)
surgery is also used in patients after KD for severe obstructive
lesions, and results have generally been good, especially when
the internal thoracic artery is used.83 85 86 In the setting of giant
coronary aneurysms without signiﬁcant obstruction, CABG may
be ineffective in preventing myocardial infarction, as graft
patency may be compromised by competing ﬂow from the
native coronary artery.83 85 86
Recommendations for long-term cardiac management
A detailed review of this area is beyond the scope of this article.
A statement of the American Heart Association committee on
rheumatic fever, endocarditis and KD published in 2004 pro-
vided detailed guidance on the stratiﬁcation of KD patients
according to their relative risk of myocardial ischaemia.6
Risk-level categories are summarised in table 4. This stratiﬁca-
tion allows for patient management to be individualised with
respect to medical therapy to reduce the risk of thrombosis,
physical activity, frequency of clinical follow-up and diagnostic
testing, and indications for cardiac catheterisation and coronary,
CT and MR angiography.6 Stress echocardiography when con-
sidered safe by cardiologists, should be performed on all
patients with persistent structural abnormalities of the coronary
arteries.6 If there is evidence of inducible ischaemia, then inva-
sive angiography is indicated.6 For these patients, bi-annual
follow-up and aggressive management of traditional cardiovas-
cular risk factors is also recommended for all patients.6 CT cor-
onary artery calcium scores are linked to mortality in
atherosclerosis; it has been suggested that this imaging modality
could have an important role in the late follow-up of KD.87
Adolescents and young adults may develop coronary calciﬁca-
tion that is detectable only more than 10 years after the acute
KD episode; while promising as a potential means of stratifying
patients for a long-term follow-up, it is not yet known in KD
exactly how coronary artery scores relate to late morbidity or
mortality.
At the time of this writing, a long-term follow-up study of
premature atherosclerosis/late KD vasculopathy is ongoing in
the UK; it is anticipated that this study will help guide clinicians
regarding long-term follow-up after KD.
UPDATED CLINICAL GUIDELINE FOR THE MANAGEMENT
OF KD
Since the recognition that IVIG could reduce the morbidity and
mortality of KD, treatment of this condition has been largely
protocol driven. Although authorities differ in their advocacy
for a variety of treatment protocols, it is likely that the success
of therapeutic intervention in KD is due to modulation of the
causes and/or propagators of inﬂammation. As such we have
re-evaluated the current prescriptive approach to the manage-
ment of KD in the light of the published literature, adding corti-
costeroids into primary therapy for severe and IVIG
unresponsive cases; and suggesting a role for anti-TNF- α if sys-
temic inﬂammation persists despite IVIG, aspirin and corticos-
teroids. Repeated protocol-driven administration of IVIG in
patients with little evidence of clinical and/or laboratory
improvement may be detrimental, and treatment with corticos-
teroids and/or anti-TNFα considered. Unchecked inﬂammation
damages the vasculature in KD; the acute-phase response, par-
ticularly CRP, combined with clinical response can be used to
assess the efﬁcacy of any intervention. A minimum of three
echocardiograms should be performed in the ﬁrst 6 weeks of
the illness. The justiﬁcation for this is: (1) some patients (albeit
a minority) can develop CAA in the ﬁrst week of the illness,6
and early detection of these should prompt more aggressive
primary management; (2) early echocardiography (in the ﬁrst
week) may detect extracoronary manifestations, such as mitral
regurgitation or pericardial effusion, that may be associated
with increased risk of CAA62 (3) early detection of CAA pro-
gression and/or development of thrombus might be detected
that could result in intensiﬁcation of anti-inﬂammatory and/or
additional anticoagulation therapy. With this philosophy in
mind, and in light of the therapeutic advances discussed above,
we present an updated clinical guideline9 for the management
of KD in the UK (ﬁgure 1).
AREAS FOR FUTURE RESEARCH AND CONCLUSIONS
The therapeutic uncertainties raised by the recent studies and
are highlighted above, can only be answered by further
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Table 4 Risk stratification and follow-up recommendations for children with Kawasaki disease6
Risk level Pharmacological therapy Physical activity Follow-up and diagnostic testing Invasive testing
Level I (no coronary artery
changes at any stage of illness)
None beyond first 6–8 weeks No restrictions beyond first 6–8 weeks Cardiovascular risk assessment, counselling at
5-year intervals
None recommended
Level II (transient coronary
artery ectasia that disappears
within 6–8 weeks)
None beyond first 6–8 weeks No restrictions beyond first 6–8 weeks Cardiovascular risk assessment, counselling at
3-year to 5–year intervals
None recommended
Level III (one small-medium
coronary artery aneurysm/major
coronary artery)
Low-dose aspirin (3–5 mg/kg aspirin per day), at
least until aneurysm regression documented
For patients <11y old, no restriction beyond 1st 6–
8 weeks; patients 11– 20 years old, physical activity
guided by biennial stress test, myocardial perfusion
scan; contact or high-impact sports discouraged for
patients taking antiplatelet agents
Annual cardiology follow-up with echocardiogram
+ECG, combined with cardiovascular risk
assessment, counselling; biennial stress test/
evaluation of myocardial perfusion scan; consider
CAA imaging using CT or MR angiography
Angiography, if non-invasive test suggests
ischaemia
Level IV (>1 large or giant
coronary artery aneurysm, or
multiple or complex aneurysms
in same coronary artery, without
obstruction)
Long-term antiplatelet therapy combined with
warfarin (target INR 2.0–2.5) or low
molecular-weight heparin (target: antifactor Xa
level 0.5–1.0 U/mL) should be considered in all
patients with giant aneurysms
Contact or high-impact sports should be avoided
because of risk of bleeding; other physical activity
recommendations guided by stress test/evaluation
of myocardial perfusion scan outcome
Biannual follow-up with echocardiogram +ECG;
annual stress test/evaluation of myocardial
perfusion scan 1st angiography at 6–12 mo or
sooner if clinically indicated; repeated angiography
if non-invasive test, clinical, or laboratory findings
suggest ischemia; elective repeat angiography
under some circumstances; consider CAA imaging
using CT or MR angiography
1st angiography at 6–12 months or sooner
if clinically indicated; repeated angiography
if non-invasive test, clinical, or laboratory
findings suggest ischaemia; elective repeat
angiography under some circumstances
Level V (coronary artery
obstruction)
Long-term low-dose aspirin; warfarin or low
molecular-weight heparin if giant aneurysm
persists; consider TPA to dissolve clot; consider
use of β-blockers to reduce myocardial O2
consumption; consider statins and/or ACE
inhibitors
Contact or high-impact sports should be avoided
because of risk of bleeding; other physical activity
recommendations guided by stress test/myocardial
perfusion scan outcome
Biannual follow-up with echocardiogram and ECG;
annual stress test/evaluation of myocardial
perfusion scan
Angiography recommended to address
therapeutic options; consider CAA imaging
using CT or MR angiography intermittently
to monitor
CAA, coronary artery aneurysms;; TPA, tissue plasminogen activator.
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randomised trials and immunopathological studies to address
the issues of patient selection, dose, route and safety of cortico-
steroid and/or other anti-inﬂammatory agents. The ongoing
BPSU study will provide important data regarding current epi-
demiology, CAA rates, and mortality of KD in the UK. Studies
are also needed to identify biomarkers and clinical scores that
work outside of Japan to identify patients at highest risk of
CAA and, hence, the need for the addition of corticosteroids
and/or anti-TNF in the primary treatment. Concerted inter-
national efforts aiming at improving our understanding of the
potential infectious trigger, and genetic contribution to KD
disease susceptibility or complications are of utmost importance
Whether or not KD predisposes to premature atherosclerosis, or
more correctly, late-KD vasculopathy, is the subject of an
ongoing UK study, and will help provide an evidence base to
inform long-term management strategies in the UK. Last, a sig-
niﬁcant challenge that remains is to coordinate transitional care
of KD patients into adulthood. In the UK, this is currently done
suboptimally, and the development of local networks to transi-
tion cardiac care from paediatrics through adolescence and into
adulthood are urgently required.
In conclusion, in addition to the worldwide effort to under-
stand the genetics of KD, it is time for a concerted drive to
improve the evidence base for acute and lifelong management
of this important childhood disease in the UK. As KD is a rare
disorder, research to improve understanding of the aetiology,
pathogenesis, treatment and outcome requires multicentre col-
laboration as in, for example, a recent and ongoing National
Institute for Health Research (NIHR) multicentre study of KD
in the UK.
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